E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
metastatic colorectal cancer |
|
E.1.1.1 | Medical condition in easily understood language |
advanced colorectal cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052362 |
E.1.2 | Term | Metastatic colorectal cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the median progression free survival defined as the time from randomization to disease progression according to RECIST criteria (Version 1.1) or death from any cause
|
|
E.2.2 | Secondary objectives of the trial |
- Disease control rate and response rate - Treatment-related toxicity (NCI CTC V4.0) - Overall survival - Quality of life |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
- Pharmacokinetic - Pharmacogenetic - Predictive CTC biomarkers studie - Predictive tumoral biomarkers studie - CTC studie |
|
E.3 | Principal inclusion criteria |
- Male or female ≥ 18 years old - Histologically confirmed diagnosis of colorectal cancer - Asymptomatic or resected primary tumor - Metastatic colorectal cancer not eligible for curative surgery - At least one target lesion: - Unidimensionally measurable on cross-sectional imaging - In an area not previously irradiated - Disease progression after failure of active drugs (5-Fu or 5-Fu prodrugs, irinotecan, oxaliplatin, bevacizumab) - WHO performance status ≤ 2 - Confirmation of KRAS mutation in codons 12 or 13 in the primary tumor or metastases - Total bilirubin ≤ 1.5 ULN, ALT or AST ≤ 2.5 ULN (or < 5 in case of liver impairment) - Haemoglobin ≥ 10 g/dL, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3 - Amylase and lipase < 1.5 ULN - Serum creatinine ≤ 1.5 ULN - Negative pregnancy test in women of childbearing potential - Use of an effective contraceptive method during the whole treatment and up to 3 months after the completion of treatment - Life expectancy > 3 months - Informed consent signed prior any study specific procedures. |
|
E.4 | Principal exclusion criteria |
- History of Gilbert’s syndrome - Symptomatic brain metastases or carcinomatous meningitis - Bone-only metastases - History or presence of other cancer within the past 5 years (except curatively treated nonmelanoma skin cancer) - Prior surgery or radiotherapy within 4 weeks before entering the study - Cardiac arrhythmia requiring treatment (except for beta-blockers and digoxin), unstable cardiac disease, myocardial infarction within the previous 6 months, > grade II NYHA heart failure, uncontrolled hypertension - History of epileptic seizures requiring long-term anticonvulsant therapy - History of organ transplantation with use of immunosuppression therapy - Severe bacterial or fungal infection (Grade > 2 NCI-CTCAE v.3.0) - HIV infection - Long-term use of CYP 3A4 enzyme-inducing agents such as rifampicin, St. John's Wort (hypericum perforatum), phenytoin, carbamazepine, phenobarbital, dexamethasone, and ketoconazole - Pregnant or breastfeeding women - Bowel malabsorption or extended bowel resection that could affect the absorption of sorafenib, occlusive syndrom, inability to take oral medications - Inflammatory bowel disease with chronic diarrhea (NCI N+Bethesda ≥ 1.2g) - Participation in another clinical trial 30 days prior to study entry - Concurrent treatment with any other investigational product or anticancer therapy (except for irinotecan or sorafenib) - Psychological, social, geographical disorders or any other condition that would preclude study compliance (treatment administration and study follow-up).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary assessment criterion is the median progression free survival (PFS), evaluated according to the RECIST criteria (v1.1) by chest-abdomen-pelvis CT-scan every 8 weeks. A complete or partial response will have to be confirmed 4 weeks after the initial observation. All responses will be reviewed by a panel of independent radiologists. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |